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Abstract
Introduction: As a result of drug sequestration and increased volume of distribution, the extracorporeal membrane
oxygenation (ECMO) procedure might lead to a decrease in drug concentrations during a patient’s treatment. The
aim of this study was to evaluate sedative, antibiotic and immunosuppressive drug loss in ECMO circuit using
ex-vivo and in-vitro experiments.
Methods: Blood concentrations of propofol, midazolam, cyclosporine and vancomycin were measured in an ex-vivo
ECMO circuit primed with whole human blood, and compared to controls stored in polypropylene tubes. In vitro
experiments were also conducted to further explore the role of temperature, oxygen exposure and
polyvinylchloride surfaces on propofol loss in the ECMO circuit.
Results: Propofol concentration decreased rapidly; 70% of its baseline concentration was lost after only 30 minutes,
and only 11% remained after five hours (P <0.001 for the comparison with control polypropylene tube propofol
concentration). Further experiments demonstrated that oxygen exposure and contact with polyvinylchloride tubing
were respectively responsible for 70% and 85% of propofol loss after 45 minutes. Midazolam concentration also rapidly
decreased in the ECMO circuit, with only 54% and 11% of baseline concentration being detected at 30 minutes and
24 hours respectively (P = 0.01 versus control). Alternatively, cyclosporine concentration remained stable for the five first
hours, then decreased to 78% and 73% of the baseline value after 24 hours and 48 hours, (P = 0.35 versus control).
Lastly, vancomycin concentration remained stable in the ECMO circuit for the 48-hour experimental protocol.
Conclusions: We observed important losses of propofol and midazolam, while cyclosporine concentration decreased
slowly and moderately, and vancomycin concentration remained unchanged in the ex-vivo ECMO circuit primed with
whole human blood. These data might help intensive care unit physicians planning clinical trials with a final objective
to better adapt doses of these drugs while treating critically ill ECMO patients.
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Introduction
Extracorporeal membrane oxygenation (ECMO) is a
complex life-support technique used to rescue critically
ill patients with severe respiratory or cardiac failure [1].
Modern ECMO circuits consist of polyvinyl chloride
(PVC) tubing, a polymethylpentene membrane oxygenator
and a centrifugal pump [2]. Patients on ECMO require
multiple medications including sedatives, analgesics, anti-
biotics and sometimes immunosuppressive drugs [3,4].
Pharmacokinetics of drugs administered during ECMO is
complex notably due to a larger volume of distribution in
ECMO-treated patients and also to the adsorption of
drugs on the PVC tubing and/or the membrane oxygenator
leading to an increase in drug clearance [2,5]. The degree of
drug uptake by the circuit depends on the physicochemical
characteristics of the drugs [6]. For example, compounds
with a high octanol/water partition (log P) will be very sol-
uble in organic materials and may exhibit considerable loss
in the ECMO circuit [6]. Conversely, the pharmacokinetics
of hydrophilic drugs have been reported to be unaffected
by the ECMO procedure [7,8]. Drug adsorption on the
circuit may also depend on circuit duration of use, since
binding sites may become saturated after a few hours
of operation [3,9].
To date, very limited data on the pharmacokinetics of
drugs in patients supported by ECMO are available. The
objective of the present study was, therefore, to determine,
in an ex vivo ECMO circuit primed with human
whole blood, changes in the concentrations of propofol,
midazolam, vancomycin and cyclosporine, which are
frequently prescribed to ECMO patients.
Methods
Drug sequestration in an ex vivo ECMO circuit primed
with human whole blood
This study was an experimental study and did not
include any patients. Thus, it needed no ethical
approval and no patient consent was needed. Whole
ECMO circuits (Maquet®, Orleans, France) comprising
a Quadrox® membrane oxygenator, a centrifugal pump, a
heat exchanger and PVC tubing were used for ex vivo
tests. All components of the circuit were treated with
heparin (Bioline coating®, Maquet). Drug-free human
whole blood (800 mL) was used to prime the circuit. In
order to replicate the in vivo operating conditions, the
temperature of the circulating blood was set at 37°C and
circuit flow rate at 4.5 L/minute. Propofol (Dipri-
van®10 mg/mL, Fresenius, France), midazolam (Hypnovel
1 mg/mL, Roche, France), vancomycin (Vancomycine®
50 mg/mL, Sandoz, France), and cyclosporine (Sandimmun®
50 mg/mL, Novartis, France) were introduced into the circuit
to achieve final concentrations of 2 μg/mL, 30 μg/mL,
500 ng/mL and 1.2 μg/mL, respectively. Octanol/water parti-
tion coefficients of the drugs are provided in Table 1. A high
partition coefficient is associated with a high solubility in
organic materials. Human blood was provided by the
Etablissement Français du Sang (EFS) (Rungis, France).
During ex vivo ECMO runs, serial post-membrane
blood samples were obtained at 30 minutes, 1 hour,
2 hours, 3 hours, 4 hours, 5 hours, 24 hours and
48 hours after drug introduction into the circuit. Until
analysis, samples were kept at 4°C and plasma separated
and frozen at −20°C. To determine spontaneous drug
degradation, blood containing identical concentrations
of the drugs studied was kept in polypropylene tubes under
agitation at 25°C for the same time before measurements.
Propofol and midazolam concentrations were mea-
sured using high performance liquid chromatography
with an ultra-violet detector (Waters, Milford, MA,
USA). Vancomycin and cyclosporine concentrations were
measured using an immuno-enzymatic method on a
Dimension® system (Siemens, Munich, Germany).
The operating conditions (oxygen flow, blood flow,
circuit temperature) remained stable during the 48 hours
of each experiment which were repeated three times with
three different ECMO circuits.
Impact of temperature, oxygen and polyvinylchloride
surfaces on propofol concentrations in vitro
To further explore the role of temperature, oxygen exposure
and PVC surfaces on propofol loss in the ECMO circuit,
the following experiments were conducted. A polypropylene
tube containing human whole blood was spiked with the
propofol stock solution to obtain a concentration of 2 μg/L.
The effect of the temperature, oxygen exposure and contact
with PVC surfaces were assessed by incubating the tube at
37°C, applying oxygen (1 L/minute) for 10 seconds to the
preparation and by distributing the preparation into 5-cm
PVC tubes, respectively. Polypropylene tubes containing
blood and propofol at the same concentration were stored
at room temperature and were used as controls. Propofol
concentrations were measured at 0 minutes, 5 minutes,
10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes
and 45 minutes from each preparation. These experiments
were conducted in triplicate.
Statistical analyses
Changes of mean drug concentrations over time were
compared between control and experimental conditions
Table 1 Octanol/water partition coefficients of propofol,
midazolam, cyclosporine and vancomycin
Drug Partition coefficient (log P)
Vancomycin - 3.1
Cyclosporine 2.9
Midazolam 3.9
Propofol 4.0
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by modeling using a linear mixed effect model. This
model accounts for the repeated responses from the
same experiments by using a random effect on inter-
cept solely (propofol and vancomycin) and using a
random effects on intercept and time (midazolam
and cyclosporine). Model choice was guided by the
lowest Akaike criteria value. The mixed effect model
was then fitted with R software version 3.0.2 and the
‘nlme’ library [10].
Results
Changes in drug concentrations in ex vivo circuits primed
with whole human blood
Propofol, midazolam, cyclosporine and vancomycin
concentrations remained stable over time in control
polypropylene tubes. Alternatively, propofol concen-
tration decreased rapidly in the ECMO circuit, 70% of
its baseline concentration being lost only 30 minutes
after introduction of the drug into the circuit (Figure 1).
After 5 hours, only 11% of the initial propofol concentra-
tion remained and the fraction remaining beyond 24 hours
was negligible. Differences between experiment and
control polypropylene tube propofol concentrations
were statistically significant (P = 0.0006). Midazolam
concentration also decreased rapidly in ECMO circuits
(Figure 2), with only 54% and 11% of baseline concen-
trations being detected at 30 minutes and 24 hours,
respectively (P = 0.01 versus polypropylene control).
The cyclosporine concentration remained stable in
the circuit for the first 5 hours, then decreased to
78% and 73% of the baseline value after 24 hours and
48 hours, respectively (P = 0.35 versus polypropylene
control) (Figure 3). In contrast, vancomycin concen-
tration remained stable in the ECMO circuit during
the 48 hours of the experimental protocol (P = 0.86)
(Figure 4).
Impact of temperature, oxygen and PVC surfaces on
propofol concentration in vitro
Oxygen exposure and contact with PVC tubing resulted
in 70% and 85% loss of propofol after 45 minutes,
respectively. Alternatively, heating the polypropylene
tube to 37°C had no effect on propofol concentration
(Figure 5).
Discussion
This study showed important losses of propofol and
midazolam in ex vivo ECMO circuits primed with
whole human blood, while cyclosporine concentration
decreased slowly and moderately and vancomycin
concentration remained unchanged. Furthermore, we
demonstrated that oxygen exposure and contact with
PVC tubing were major factors leading to propofol
degradation in ECMO circuits.
Patients on ECMO frequently receive many drugs, such
as sedatives and analgesics, antibiotics or immunosuppres-
sants. Inadequate blood concentration of these drugs might
lead to treatment failure or toxicity, underlining the need
for better knowledge of the complex pharmacokinetics
and pharmacodynamics in this particular setting
[11,12]. Indeed, drug concentrations in critically ill ECMO
patients might be altered by an increase in drug volume
of distribution or alteration in drug elimination.
Drugs might also be adsorbed in the ECMO circuit,
with greater loss being reported for more lipophilic
and higher octanol/water partition coefficient drugs
(Table 1) [6,13-16].
Consistent with previous reports [1,17], we observed
a rapid and major decrease in propofol concentration
in our experiments. Although its lipophilic properties
might be associated with substantial loss due to adsorp-
tion on circuit components, our results suggested that
oxidation might also be an important determinant of
Propofol
0%
20%
40%
60%
80%
100%
120%
140%
0 0.5 1 2 3 4 5 24 48
Time (h)
%
 d
ru
g
 r
e
m
a
in
in
g
Control
Circuit
Figure 1 Percentage of propofol remaining in the ECMO circuit according to time (mean ± standard error of the mean; n = 3). ECMO,
extracorporeal membrane oxygenation.
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propofol degradation. Indeed, propofol is a reducing agent
which can be oxidized in the presence of an electron
acceptor [18].
The decrease in midazolam concentration was rapid
and only 25% of the initial concentration remained in
the circuit after 24 hours. This observation is also
consistent with previously reported in vitro and ex vivo
data on midazolam concentration evolution in ECMO
circuits, with the decrease reaching 68% to 87% after
24 hours [1,6,19].
Inadequate concentrations of antibacterial agents can
lead to treatment failure that might compromise the
outcomes of critically ill patients. Vancomycin, which
is the drug of choice for treating beta-lactam resistant
Gram-positive bacteria, is frequently prescribed to
ECMO patients. Data on vancomycin concentrations
reported in ECMO are controversial. In agreement
with our observation, Mehta et al. [20] and Shekar et al.
[19], using ex vivo models, found that vancomycin levels
remained unchanged in the circuit for 24 hours.
Conversely, Dagan et al. observed that vancomycin
concentrations decreased by 36% when the drug was
introduced in a new circuit while it decreased by
only 11% when introduced in a circuit which had
been running for five days [3]. Saturation of adsorption
sites was suggested by these authors [3]. Similarly,
Wildschut et al. also reported a decrease in vancomycin
concentration (up to 46%) in a study conducted with
neonatal and pediatric circuits [6]. These observations
suggest that more data are needed to better determine
changes in drug concentrations of vancomycin in an
ECMO circuit.
Midazolam
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Figure 2 Percentage of midazolam remaining in the ECMO circuit according to time (mean ± standard error of the mean; n = 3). ECMO,
extracorporeal membrane oxygenation.
Cyclosporine
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Figure 3 Percentage of cyclosporine remaining in the ECMO circuit according to time (mean ± standard error of the mean; n = 3).
ECMO, extracorporeal membrane oxygenation.
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Immunosuppressive agents, such as cyclosporine, are
defined by a narrow therapeutic window and low serum
concentrations of these drugs might lead to acute graft
rejection. Although a previous study suggested in vitro
adsorption studies of cyclosporine on PVC infusion sets
significantly higher than that in those made of polyethylene
or polybutadiene [21], this study is the first to evaluate
cyclosporine pharmacokinetics in ECMO patients.
Our results suggested that cyclosporine concentration
decreases slowly in the ECMO circuit with 66% of the
initial concentration remaining in the circuit after
48 hours. This decrease might be attributed in part to
adsorption on the ECMO circuit component, given its
high partition coefficient (log P = 2.92).
Conclusions
We reported herein on propofol, midazolam, vancomycin
and cyclosporine concentration profiles in ex vivo
whole-blood primed ECMO circuits. Our observations
showed important losses of propofol and midazolam,
while cyclosporine concentration decreased slowly and
moderately and vancomycin concentration remained
unchanged. These data might help intensive care unit
physicians better adapt doses of these drugs while treating
critically ill ECMO patients. Further studies should focus
on the in vivo pharmacokinetics of drugs during ECMO.
Key messages
 This paper confirmed important loss of lipophilic
drugs within ECMO circuits.
 It also highlighted the role of oxidation as an
influencing factor of ex vivo stability of reducing
drugs.
 Drug properties should be taken into account for
therapeutic strategy in ECMO patients.
Vancomycin
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Figure 4 Percentage of vancomycin remaining in the ECMO circuit according to time (mean ± standard error of the mean; n = 3). ECMO,
extracorporeal membrane oxygenation.
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